Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Spero Therapeutics Inc (SPRO)
NASDAQ:SPRO
Holding SPRO?
Track your performance easily
Earnings Data
Report Date
Mar 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.31Last Year’s EPS
0.96Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 08, 2018
|% Change Since: -27.20%
|Next Earnings Date:Aug 09, 2018
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical developments and financial growth, supported by strategic partnerships. However, challenges such as the departure of a key executive and increased R&D expenses leading to a higher net loss were also noted.Company Guidance
In the Spero Therapeutics second quarter 2024 earnings call, key guidance metrics were discussed, particularly focusing on their lead drug candidates SPR720 and tebipenem HBr. SPR720 is advancing as a first-line oral agent for nontuberculous mycobacterial pulmonary disease (NTM-PD), with an estimated patient population of 245,000 across the U.S., EU, and Japan. Data from its Phase IIa trial, which enrolled 25 patients, are expected in Q4 2024. The trial compares two doses (500 mg and 1,000 mg) against a placebo, with primary and secondary endpoints including changes in bacterial load and time to positivity, respectively. Meanwhile, the Phase III PIVOT-PO trial for tebipenem HBr, aimed at treating complicated urinary tract infections, is on track to complete enrollment by the second half of 2025, targeting 2,648 patients. The primary endpoint is overall response, with a 10% non-inferiority margin. Financially, Spero ended Q2 with $63.5 million in cash and anticipates additional milestone payments from GSK, projecting sufficient funding into late 2025. Total revenue for Q2 2024 was reported at $10.2 million, compared to $2.7 million in Q2 2023, primarily driven by collaboration and grant revenues.SPR720 Clinical Development Progress
Spero Therapeutics is advancing SPR720 as a first-line oral agent for nontuberculous mycobacterial pulmonary disease (NTM-PD). They expect to share comprehensive data from ongoing and completed clinical studies in Q4, including data from a Phase IIa proof of concept study and two supportive Phase I studies.
Tebipenem HBr Phase III Enrollment on Track
Enrollment for the Phase III PIVOT-PO trial for tebipenem HBr, developing as the first potential oral carbapenem antibiotic for cUTI, is on track with completion expected in the second half of 2025.
Strong Financial Position and Revenue Growth
Ended Q2 2024 with $63.5 million in cash and equivalents. Total revenue for Q2 2024 was $10.2 million, a significant increase from $2.7 million in Q2 2023, primarily due to increased collaboration and grant revenue.
Partnerships and Funding
Spero has ongoing partnerships with GSK and Pfizer, and anticipates receiving three remaining tranches of development milestone payments from GSK totaling approximately $24 million every six months.
---
SPRO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SPRO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $1.25 | $1.18 | -5.60% |
| Aug 05, 2024 | $1.34 | $1.27 | -5.22% |
| May 15, 2024 | $1.62 | $1.57 | -3.09% |
| Mar 13, 2024 | $1.66 | $1.74 | +4.82% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Spero Therapeutics Inc (SPRO) report earnings?
Spero Therapeutics Inc (SPRO) is schdueled to report earning on Mar 13, 2025, TBA Not Confirmed.
What is Spero Therapeutics Inc (SPRO) earnings time?
Spero Therapeutics Inc (SPRO) earnings time is at Mar 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SPRO EPS forecast?
SPRO EPS forecast for the fiscal quarter 2024 (Q4) is -0.31.
---